|
Status |
Public on Dec 10, 2010 |
Title |
ASSAGE_breast_epithelium_normal_N1 |
Sample type |
SRA |
|
|
Source name |
reduction mammoplasty
|
Organism |
Homo sapiens |
Characteristics |
tissue: breast cell type: epithelial cell disease state: normal cell marker: CD24+
|
Extracted molecule |
polyA RNA |
Extraction protocol |
ASSAGE libraries were generated essentially as described (PMID: 19056939), except that we used polyA RNA. Briefly,we treated polyA RNA with bisulfite, which changes all cytidine residues to uridine residues. We generated cDNA from bisulfite-treated RNA with reverse transcriptase, the double-stranded cDNA was used to construct libraries for sequencing following Illumina's standard genomic DNA sample preparation instructions. The sequence of a bisulfite-treated RNA molecule can only be matched to one of the two possible DNA template strands.
|
|
|
Library strategy |
RNA-Seq |
Library source |
transcriptomic |
Library selection |
cDNA |
Instrument model |
Illumina Genome Analyzer |
|
|
Data processing |
We generated a bisulfite-converted genome for both plus and minus strands (6.2 Gb) as a reference for ASSAGE reads. We used SeqMap (http://biogibbs.stanford.edu/~jiangh/SeqMap/)to align reads to the bisulfite-converted genome under default conditions, allowing up to two mismatches in 32-bp reads. We used reads that uniquely mapped to either plus or minus strand-derived sequences.
|
|
|
Submission date |
Dec 08, 2010 |
Last update date |
May 15, 2019 |
Contact name |
Kornelia Polyak |
E-mail(s) |
kornelia_polyak@dfci.harvard.edu
|
Phone |
617-632-2106
|
Organization name |
Dana-Farber Cancer Institute
|
Department |
Medical Oncology
|
Lab |
Polyak
|
Street address |
450 Brookline Ave
|
City |
Boston |
State/province |
MA |
ZIP/Postal code |
02215 |
Country |
USA |
|
|
Platform ID |
GPL9052 |
Series (2) |
GSE25292 |
Altered antisense-to-sense transcript ratios in breast cancer |
GSE25932 |
Altered antisense-to-sense transcript ratios in breast cancer: ASSAGE |
|
Relations |
SRA |
SRX033238 |
BioSample |
SAMN00149458 |